Home About Us Pipeline Investors News & Events Careers Contact Us
S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values
Clinical Trials | R&D Programmes | Technologies & Capabilities | S*BIO’s Functional Capabilities | Publications
Investors | Partnerships
News & Press Releases | Participation in Events
Join Our Team | Job Openings | How to Apply

A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it. Max Planck


Clinical Trials


S*BIO is currently conducting a dose-escalation Phase 1 clinical study to evaluate the safety and tolerability of SB939 in patients with either solid or hematological tumors.

Patients: For more information about this study on SB939, please either call +65 67722611 or email ai_bee_ong@nuh.com.sg to get in contact with the Clinical Research Manager at the Cancer Institute@National UniversityHospital




Copyright © 2002 S*BIO Pte Ltd. All rights reserved.